日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52

TASUKI-52研究中，纳武利尤单抗联合化疗和贝伐单抗治疗非鳞状非小细胞肺癌患者的四年疗效

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.70330
Lee, Jong-Seok; Sugawara, Shunichi; Kang, Jin-Hyoung; Kim, Hye Ryun; Inui, Naoki; Hida, Toyoaki; Lee, Ki Hyeong; Yoshida, Tatsuya; Tanaka, Hiroshi; Yang, Cheng-Ta; Inoue, Takako; Nishio, Makoto; Goto, Yasushi; Tamura, Tomohide; Yamamoto, Nobuyuki; Yu, Chong-Jen; Akamatsu, Hiroaki; Takahashi, Shigeru; Nakagawa, Kazuhiko
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)

TASUKI-52 简明语言摘要：一项研究，旨在探讨纳武利尤单抗联合铂类化疗和贝伐单抗作为治疗晚期或复发性非鳞状非小细胞肺癌 (NSCLC) 患者的联合疗法。

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2026.2617855
Sugawara, Shunichi; Lee, Jong-Seok; Kang, Jin-Hyoung; Kim, Hye Ryun; Inui, Naoki; Hida, Toyoaki; Lee, Ki Hyeong; Yoshida, Tatsuya; Tanaka, Hiroshi; Yang, Cheng-Ta; Inoue, Takako; Nishio, Makoto; Goto, Yasushi; Tamura, Tomohide; Yamamoto, Nobuyuki; Yu, Chong-Jen; Akamatsu, Hiroaki; Takahashi, Shigeru; Nakagawa, Kazuhiko
肺癌
肿瘤
肿瘤免疫
CLC
细胞生物学
发表日期：2026
文献求助 收藏

Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase

对评估福奈妥匹坦和顺铂诱导的恶心呕吐风险因素的研究进行汇总分析，这些风险因素发生在延长的总体阶段

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-023-02648-1
Inui, Naoki; Toi, Yukihiro; Yoneshima, Yasuto; Morise, Masahiro; Hata, Akito; Kubota, Kaoru; Saeki, Toshiaki; Tamura, Tomohide
发表日期：2023
文献求助 收藏

First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial

一线纳武利尤单抗、紫杉醇、卡铂和贝伐珠单抗治疗晚期非鳞状非小细胞肺癌：ONO-4538-52/TASUKI-52随机对照试验的最新生存分析

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.6348
Kim, Hye Ryun; Sugawara, Shunichi; Lee, Jong-Seok; Kang, Jin-Hyoung; Inui, Naoki; Hida, Toyoaki; Lee, Ki Hyeong; Yoshida, Tatsuya; Tanaka, Hiroshi; Yang, Cheng-Ta; Nishio, Makoto; Ohe, Yuichiro; Tamura, Tomohide; Yamamoto, Nobuyuki; Yu, Chong-Jen; Akamatsu, Hiroaki; Takahashi, Shigeru; Nakagawa, Kazuhiko
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE

一项随机、双盲、III期研究，比较福斯奈匹坦与福沙匹坦预防高致吐性化疗引起的恶心和呕吐的疗效：CONSOLE

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.21.01315
Hata, Akito; Okamoto, Isamu; Inui, Naoki; Okada, Morihito; Morise, Masahiro; Akiyoshi, Kohei; Takeda, Masayuki; Watanabe, Yasutaka; Sugawara, Shunichi; Shinagawa, Naofumi; Kubota, Kaoru; Saeki, Toshiaki; Tamura, Tomohide
发表日期：2022
文献求助 收藏

A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC

一项评估福斯奈妥匹坦作为止吐药用于接受蒽环类药物和环磷酰胺治疗患者的3期安全性研究：CONSOLE-BC

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.34088
Matsuura, Kazuo; Tsurutani, Junji; Inoue, Kenichi; Tanabe, Yuko; Taira, Tetsuhiko; Kubota, Kaoru; Tamura, Tomohide; Saeki, Toshiaki
发表日期：2022
文献求助 收藏

Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)

比较福沙匹坦与福沙匹坦预防高致吐性化疗引起的恶心和呕吐（CINV）的探索性分析：一项随机、双盲、3期研究（CONSOLE）

期刊:Oncology and Therapy
影响因子:3.2
doi:10.1007/s40487-022-00188-2
Hata, Akito; Shiraishi, Yoshimasa; Inui, Naoki; Okada, Morihito; Morise, Masahiro; Akiyoshi, Kohei; Takeda, Masayuki; Watanabe, Yasutaka; Sugawara, Shunichi; Shinagawa, Naofumi; Kubota, Kaoru; Saeki, Toshiaki; Tamura, Tomohide
发表日期：2022
文献求助 收藏

Findings of virtual bronchoscopic navigation can predict the diagnostic rate of primary lung cancer by bronchoscopy in patients with peripheral lung lesions

虚拟支气管镜导航的研究结果可以预测周围型肺部病变患者通过支气管镜检查诊断原发性肺癌的概率。

期刊:BMC Pulmonary Medicine
影响因子:2.8
doi:10.1186/s12890-022-02071-2
Kitamura, Atsushi; Tomishima, Yutaka; Imai, Ryosuke; Nishimura, Naoki; Okafuji, Kohei; Ro, Shosei; Jinta, Torahiko; Tamura, Tomohide
肺癌
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

在未经治疗的转移性 EGFR 突变型非小细胞肺癌患者中，雷莫芦单抗联合厄洛替尼对比安慰剂联合厄洛替尼的疗效比较：RELAY 日本亚组研究

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2021.100171
Nishio, Kazuto; Seto, Takashi; Nishio, Makoto; Reck, Martin; Garon, Edward B; Sakai, Kazuko; Goto, Koichi; Kato, Terufumi; Nakanishi, Yoichi; Takahashi, Toshiaki; Yamamoto, Nobuyuki; Kiura, Katsuyuki; Ohe, Yuichiro; Tamura, Tomohide; Visseren-Grul, Carla; Frimodt-Moller, Bente; Hozak, Rebecca R; Wijayawardana, Sameera R; Zimmermann, Annamaria; Homma, Gosuke; Enatsu, Sotaro; Nakagawa, Kazuhiko
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2021
文献求助 收藏

Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial

S-1 与多西他赛在既往接受过铂类化疗的晚期非小细胞肺癌老年患者中的疗效和安全性比较：EAST-LC 试验的亚组分析

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2021.100142
Yang, James Chih-Hsin; Mok, Tony S K; Lu, Shun; Nakagawa, Kazuhiko; Yamamoto, Nobuyuki; Shi, Yuan-Kai; Zhang, Li; Soo, Ross A; Morita, Satoshi; Tamura, Tomohide
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏